Mehmet Fatih Deveci, Ismail Kursad Gokce, Huseyin Kaya, Ramazan Ozdemir

Extensively drug-resistant acinetobacter baumannii meningitis which successfully treated with tigecycline; a case report of preterm newborn

Acinetobacter baumannii (A. baumannii) meningitis is a state difficult to treat with a high mortality rate, since antibiotics have low CSF penetration level and antibiotic resistance is frequently encountered. Multidrug-resistance is common in hospital-acquired A. baumannii infections, and in these cases, colistin treatment is frequently used as the last option. Colistin-resistant A. baumannii infections are reported in recent years. We present a case of preterm newborn who developed extensively drug-resistant (carbapenem and colistin resistance) A. baumannii meningitis after ventriculoperitoneal shunt operation. Although not approved in children, combined intravenous treatment including tigecycline, meropenem and colistin provides clinical and bacteriological recovery in colistin and carbapenem-resistant A. baumannii meningitis

PDF

___

1. Vinodkumar CS, Neelagund YF. Acinetobacter septicaemia in neonates. Indian J Med Microbiol 2004;22:71.
2. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: Mechanisms and epidemiology. Clin Microbiol Infect 2006;12:826-36.
3. Turner PJ, Greenhalgh JM. MYSTIC StudyGroup (Europe). The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997 2000. Clin Microbiol Infect 2003;9:563- 7.
4. Cai Y, Chai D, Wang R, et al. Colistin resistance of Acinetobacterbaumannii:clinicalreports,mechanisms and antimicrobial strategies. J Antimicrob Chemother. 2012;67:1607-15.
5. Polat M, Ozkaya-Parlakay A. Tigecycline salvage therapy for ventriculoperitoneal shunt meningitis due to extensively drug-resistant Acinetobacter baumannii. Eur J Pediatr 2019;178:117-8.
6. Mondal GP, Raghavan M, Bhat BV, et al. Neonatal septicaemia among inborn and outborn babies in a referral hospital. Indian J Pediatr 1991;58:529-33.
7. Shete VB, Ghadage DP, Muley VA, et al. Acinetobacter septicemia in neonates admitted to intensive care units. J Lab Physicians 2009;1:73-6.
8. Metan G, Alp E, Aygen B, et al. Carbapenem-resistant Acinetobacter baumannii: an emerging threat for patients with post-neurosurgical meningitis. Int J Antimicrob Agents 2007;29:112-3.
9. Korinek AM, Baugnon T, Golmard JL, et al. Risk factors for adult nosocomial meningitis after craniotomy: role of antibiotic prophylaxis. Neurosurgery 2008;62:532- 9.
10. Bonomo RA, Szabo D. Mechanisms of multidrug- resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006;43:49-56.
11. Karaiskos I, Galani L, Baziaka F, et al. Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literatüre review. Int J Antimicrob Agents 2013;41:499-508.
12. Hejnar P, Kolár M, Hájek V. Characteristics of Acinetobacter strains (phenotype classification, antibiotic susceptibility and production of beta- lactamases) isolated from haemocultures from patients at the Teaching Hospital in Olomouc. Acta Univ Palacki Olomuc Fac Med 1999;142:73-7.
13. Tasina E, Haidich AB, Kokkali S, et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011;11:834-44.
14. Ray L, Levasseur K, Nicolau DP, et al. Cerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis. Ann Pharmacother 2010;44:582-6.
15. Principe L, D’Arezzo S, Capone A, et al. Invitro activity of tigecycline in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii. Ann Clin Microbiol Antimicrob. 2009;8:1-10.